Circulating nucleosomes and response to chemotherapy:: An in vitro, in vivo and clinical study on cervical cancer patients

被引:52
|
作者
Trejo-Becerril, C
Pérez-Cárdenas, E
Treviño-Cuevas, H
Taja-Chayeb, L
García-López, P
Segura-Pacheco, B
Chávez-Blanco, AC
Lizano-Soberon, M
González-Fierro, A
Mariscal, I
Wegman-Ostrosky, T
Dueñas-González, A
机构
[1] INCAN, IIB, Unidad Invest Biomed Canc, Mexico City, DF, Mexico
[2] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico
关键词
circulating nucleosomes; ELISA; cervical cancer; neoadjuvant chemotherapy;
D O I
10.1002/ijc.11003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is known that cell-free DNA circulates in plasma/serum of patients with cancer and that part of this DNA circulates as nucleosomes that can be quantified by ELISA. We analyzed the effect of tumor and chemotherapy upon the levels of nucleosomes in vitro, in vivo and in cervical cancer patients. The levels of nucleosomes pre- and post-treatment were correlated with response in I I patients receiving chemotherapy. Nucleosomes were determined in nude mice treated with or without cisplatin and carrying tumors generated with HeLa cells, and in the cell lysate and supernatant of HeLa cells exposed to cisplatin in culture. In addition, nucleosomes were determined at different time points in patients and in rats receiving chemotherapy. Nucleosomes were higher in patients that controls (1,760 vs. 601, p = 0.0001). After 24 hr of treatment with oxaliplatin and gemcitabine, the levels decreased in 6 patients of whom Shad response. Nucleosome levels differed between mice xenografted and not xenografted (765 vs. 378, p = 0.001) and between xenografted treated with or without cisplatin (650 vs. 765, p = 0.010), but not in tumor-free animals treated and untreated with cisplatin (378 vs. 379, p = 0.99). In vitro, nucleosomes reached at peak 8 hr in cell lysates to decrease thereafter, whereas in supernatant, levels continued to increase up to 24 hr. Serial determination of nucleosomes in patients showed a rise within 6-12 hr and then a reduction to below the basal at 24 hr. In rats, nucleosomes had no major changes in those receiving oxaliplatin or the triple combination of cisplatin, gemcitabine and paclitaxel as compared to untreated controls. An overdose of this triple combination produced a transient elevation of almost 1,000 AU over the basal. Our results demonstrate that most of circulating nucleosomes originate from the tumor and that chemotherapy produces an early rise most likely due to, tumor apoptosis and that nucleosomes are rapidly cleared from circulation. On the contrary, chemotherapy within the therapeutic range of doses has no effect on nucleosome levels in healthy mice and,rats. This data suggests that the determination of circulating nucleosomes pre- and post-treatment could be a useful test to predict response to chemotherapy in cancer patients. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:663 / 668
页数:6
相关论文
共 50 条
  • [31] Topoisomerase levels determine chemotherapy response in vitro and in vivo
    Burgess, Darren J.
    Doles, Jason
    Zender, Lars
    Xue, Wen
    Ma, Beicong
    McCombie, W. Richard
    Hannon, Gregory J.
    Lowe, Scott W.
    Hemann, Michael T.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (26) : 9053 - 9058
  • [32] "Initial Clinical Response" to Neoadjuvant Chemotherapy: An In-vivo Chemosensitivity Test for Efficacy in Patients with Advanced Breast Cancer
    Khokher, Samina
    Mahmood, Saqib
    Qureshi, Muhammad Usman
    Khan, Saeed Akhtar
    Chaudhry, Naseer Ahmad
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (04) : 939 - 946
  • [33] The Course of Circulating Nucleosomes in Liver Cancer Patients Undergoing Transarterial Chemoembolization Therapy
    Kohles, Nikolaus
    Nagel, Dorothea
    Juengst, Dietrich
    Durner, Juergen
    Stieber, Petra
    Holdenrieder, Stefan
    CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM, 2011, : 73 - 77
  • [34] FDG PET/CT in monitoring neoadjuvant chemotherapy response in cervical cancer patients
    Chang, Hsiu-Ping
    Ueng, Shir-Hwa
    Lai, Chyong-Huey
    Chang, Ting-Chang
    Chou, Hung-Hsueh
    Hsueh, Swei
    Yen, Tzu-Chen
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [35] Correlation of histone methyl marks with circulating nucleosomes in blood plasma of cancer patients
    Gezer, Ugur
    Mert, Ufuk
    Ozgur, Emre
    Yoruker, Ebru E.
    Holdenrieder, Stefan
    Dalay, Nejat
    ONCOLOGY LETTERS, 2012, 3 (05) : 1095 - 1098
  • [36] Circulating HPV DNA in Cervical Cancer Patients
    Cheung, T. H.
    Chan, K. S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 131 - 131
  • [37] Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer.: Predictive and prognostic significance -: art. no. 65
    Trejo-Becerril, C
    Oñate-Oñate, LF
    Taja-Chayeb, L
    Vanoye-Carlo, A
    Cetina, L
    Duenas-González, A
    BMC CANCER, 2005, 5 (1)
  • [38] Neoadjuvant Chemotherapy in Pregnant Patients with Cervical Cancer: A Monocentric Retrospective Study
    Bernardini, Federica
    Ferrandina, Gabriella
    Ricci, Caterina
    Fagotti, Anna
    Fanfani, Francesco
    Cavaliere, Anna Franca
    Gui, Benedetta
    Scambia, Giovanni
    De Vincenzo, Rosa
    CURRENT ONCOLOGY, 2022, 29 (08) : 5702 - 5714
  • [39] Feasibility of Radio-Chemotherapy in Patients with Cervical Cancer: Clinical Practice Outside of Clinical Trials
    Ewald-Riegler, N.
    Harter, P.
    Buhrmann, C.
    Heitz, F.
    Kommoss, S.
    Haberstroh, M.
    Gomez, R.
    Traut, A.
    Prott, F. J.
    du Bois, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2010, 70 (05) : 385 - 390
  • [40] The impact of frailty on chemotherapy intolerance in patients with cervical cancer: A longitudinal study
    Wang, Yanhong
    Zhang, Yaya
    Liang, Xueping
    Liu, Jin
    Zhao, Yanan
    Su, Qingling
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2025, 74